The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.